We and others have demonstrated the ability of granulocyte-macrophage colony-stimulating factor (GM-CSF) to suppress autoimmunity by increasing the number of CD4 + CD25
Introduction
Myasthenia gravis (MG) is a B cell-mediated, T cell-dependent autoimmune disease in which the primary autoantigen is the skeletal muscle acetylcholine receptor (AChR) (Meriggioli and Sanders, 2009 ). The immunopathogenesis of myasthenia gravis (MG) involves the production of high-affinity anti-AChR antibodies whose synthesis is modulated by anti-AChR CD4 + T cells (Vincent, 2002) . The activation of anti-AChR T cells is, in turn, determined by their interactions with antigenpresenting cells (APCs), consisting primarily of dendritic cells (DCs). DCs promote autoantibody synthesis by activation of T cells which provide cytokines and "help" to B cells, but also directly enhance antibody production and isotype switching (MacPherson et al., 1999; Cerutti et al., 2005) . Experimental autoimmune MG (EAMG) can be induced in mice by immunization with AChR purified from the electric organs of the electric ray, Torpedo californica (tAChR) (Christadoss et al., 2000) . In EAMG, anti-Torpedo AChR antibodies cross-react with mouse AChR and cause myasthenic symptoms (Lindstrom, 1999) . In both MG and EAMG, AChR-specific B cells produce anti-AChR antibodies that bind to the AChR at the neuromuscular junction, activate complement, and accelerate AChR destruction, culminating in neuromuscular transmission failure and fatigable muscle weakness. GM-CSF, a pleiotropic immune modulator and a potent dendritic cell (DC) growth factor, (Hamilton, 2002) , has been shown to be capable of both stimulating the immune response, endowing DCs with improved antigen presenting capacity, or alternatively suppressing the immune response by favoring the development of immature DCs that recruit Tregs (Pulendran et al., 2000; O'Keefe et al., 2002; Parmiani et al., 2007) . We and others have demonstrated the ability of low-dose GM-CSF to maintain semi-mature, tolerogenic DCs in vivo, induce Foxp3 + regulatory T cells (Tregs), and suppress autoimmunity (Vasu et al., 2003; Gangi et al., 2005; Gaudreau et al., 2007; Ganesh et al., 2009) . We have previously reported that GM-CSF effectively ameliorates EAMG in both pretreatment (Sheng et al., 2006) and therapeutic protocols (Meriggioli et al., 2008; Sheng et al., 2008) , by down-modulating anti-AChR T cell and antibody responses. GM-CSF-induced suppression of EAMG was associated with a selective expansion of CD4 (Bhattacharya et al., 2011; Ganesh et al., 2011) . Conversion of these "induced" or "adaptive" Tregs (iTregs) required T cell receptor (TCR) activation, suggesting that these cells may mediate antigen-specific suppression.
